Table II.
Intragroup and intergroup analysis of NIH-CPSI total score and symptom domain subscores, of IIEF erectile dysfunction scores, of mean urinary peak flow levels and percentage bladder voided volumes in patients affected by the inflammatory (IIIa) and non-inflammatory (IIIb) sub-categories of CP/CPPS, assessed at time-points V0, V6, V12 and V18.
| Study time-point | ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| V0 | V6 | V12 | V18 | |||||
|
|
|
|
|
|||||
| Variable | IIIa | IIIb | IIIa | IIIb | IIIa | IIIb | IIIa | IIIb |
| NIH-CPSI total score [mean ± SD, (median, IQR)] | 22.22±6.99 (22,10) | 19.99±7.03e (20,10) | 8.99±5.10 (8,5)a | 10.49±6.03g (9,8)a | 7.86±4.39 (8,4)a,b | 8.35±4.62i (8,5)a,b | 7.55±4.29 (7,4)a,b | 7.66±4.01 (8,5)a,b |
| NIH-CPSI pain score [mean ± SD, (median, IQR)] | 10.22±3.60 (10,5) | 9.02±3.46e (9,6) | 3.73±2.21 (3,2)a | 4.32±2.92g (4,3)a | 3.24±1.80 (3,2)a,b | 3.43±2.12 (3,1)a,b | 3.11±1.79 (3,2)a,b | 3.07±1.92 (3,2)a,b |
| NIH-CPSI voiding symptom score [mean ± SD, (median, IQR)] | 4.12±2.52 (4,4) | 3.91±2.64 (4,4) | 1.61±1.67 (2,2)a | 2.28±2.13g (2,4)a | 1.38±1.52 (1,2)a,b | 1.63±1.56i (2,2)a,b | 1.32±1.48 (1,2)a,b | 1.54±1.56 (1,2)a,b |
| NIH-CPSI QoL impact score [mean ± SD, (median, IQR)] | 7.90±2.86 (8,4) | 7.05±2.73e (7,4) | 3.58±2.02 (3,2)a | 3.99±2.43g (4,3)a | 3.13±1.81 (3,2)a,b | 3.31±2.18i (3,2)a,b | 3.04±1.79 (3,2)a,b | 3.01±1.76 (3,2)a,b |
| IIEF, items 1–5+15 [mean ± SD, (median, IQR)] | 23.57±5.26 (24,8) | 22.71±6.11 (24,10) | 26.52±3.81 (28,3)a | 26.15±4.44 (28,4)a | 26.39±4.81 (28,3)a | 25.87±5.04 (28,4)a | 26.32±4.70 (28,3)a | 26.02±5.66 (28,4)a |
| Urine peak flow rate (Qmax, ml/sec) (mean ± SD) | 13.76±5.30 | 15.60±7.11f | 17.92±3.94c | 18.62±5.97c | 18.29±3.55c | 19.55±4.55c,d | 18.27±3.39c | 19.37±4.10c |
| Bladder voided volume (%) (mean ± SD) | 83.25±18.96 | 85.37±18.37 | 98.95±6.00c | 97.65±8.97c,h | 99.78±3.83c | 99.48±4.75c,d | 99.33±5.01c | 99.76±3.10c |
P<0.0001 vs. V0, Wilcoxon signed rank test;
P<0.0001 vs. V6, Wilcoxon signed rank test.
P<0.0001 vs. V0, paired, two-tailed t-test;
P<0.01 vs. V6, paired, two-tailed t-test.;
P<0.001 vs. IIIa, Mann-Whitney test;
P<0.001 vs. IIIa, unpaired, two-tailed t-test.
P<0.0001 vs. IIIa, ANCOVA;
P<0.001 vs. IIIa, ANCOVA;
P<0.05 vs. IIIa, ANCOVA.
NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; IIEF, International Index of Erectile Function; SD, standard deviation; IQR, interquartile range; QoL, quality of life; ANCOVA, analysis of covariance.